Invest in General Genomics Inc.: Curo46 - Artificial Intelligence (Powered) Personalized Health Software | Wefunder
min $100
A Future Equity Agreement (SAFE) gives you the right to future shares in the company. If you invest, you're betting the company will be worth more than $50M eventually
Now, more than ever, there is a pressing need for clarity regarding medical information and solutions. We, at General Genomics, understand this
The rising uncertainties of the pandemic created concerns about personal risks and susceptibility to other health issues, not just COVID-19
What if we told you there was a way to know exactly how medical problems could affect your immune system?
With your user data and our Proprietary Predictive Algorithm, we have the solution
Curo46 uses Artificial Intelligence and our algorithm to take a holistic approach to your health. We collect data from all areas: medical history, genetic markers, consumption habits, health trackers, and more
The data collected allows us to map out trends and determine relationships or similarities you may have to others. This shows you personal links within the general population and where you may be an outlier that could experience rare symptoms
Now, instead of wondering whether you react poorly to a prescription, you will be able to how medical treatments are likely to affect you personally.could know
Curo46 applications are seemingly unlimited. Medical diagnosis, risk evaluations, and treatments need to be customized so individuals truly understand their bodily responses to external factors
With COVID-19 specifically, Curo46 has built-in functionality to predict the likelihood of severe symptoms and personal risks
With our solution, many have concerns about the safety and security of data
The data we collect remains fully anonymized and decentralized—meaning, the human is never disclosed or associated with the data
The data collected by the proprietary algorithms receives countless layers of privacy protection and is compliant with global and local privacy laws. Above all, we want to ensure your identifiable data is yours and yours alone. Only you will ever be able to see your name attached to the data
Let’s talk more about our PPAs. Why are they revolutionary?
Unlike other methods for analyzing infectious diseases that only focus on one variable, General Genomics’ PPAs compares every factor that contributes to your personal risk score
Our PPAs are based solely on data science. There are no “wishy-washy” solutions based on emotional appeal; rather we provide you with science-supported, hard facts on how your body is reacting to the environment around you (and even how that may change in the future)
All of our applications and products are patented. All future developments, if possible, will be supported and protected with future patents if awardable
General Genomics is developing the next generation of artificial intelligence-driven bio-informatics. We currently have more than 20 patents in the application phase. Below is a high-level overview of our three existing patents:
Curo46 Health Suite
Objective:
Provide general consumers control of their own health data with AI-driven insights and risk scores
Market Overview:
Electronic Medical Records (“EMR”) Market
Objective:
Enhance EMR interfaces for hospitals and medical professionals
Market Overview:
Targeted Treatments
Objective:
Customize treatments with our date to reduce side effects, costs, and improve results
Market Overview (Initial Target Applications):
Adverse Drug Reactions (ADRs)
Opioid Crisis
Pandemic Impacts
Objective:
Create models for the population’s genetic susceptibility. Engage targeted funding to support enhanced treatments and efficiently distribute immunizations to high-risk individuals. Develop plans and models for future pandemics
Market Overview (Covid-19):
Covid-19 Medical Impacts
Covid-19 Worldwide Social Economic Impacts
Covid-19 Government Funding
Covid-19 Worldwide Industry Impacts
Health Insurance
Objective:
For self-insured, improve health and reduce treatment costs of employees using Curo46 Health Suite. For insurance companies, we provide better AI/ML models in replacement of statistical methods
Market Overview:
Total Funds Raised
$50,000: Complete development of initial phase 1 application
$100,000: File patents in all other major markets. Start active online marketing campaigns
$400,000: Complete development of full Electronic Health Record interfaces, continued online marketing campaigns, expand legal setup across all states
$800,000: Bring in telemedicine and remote diagnostic functionality, expand world-wide
>$10,000,000: Look at potential partnerships and acquisition targets that are in the DNA market
Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, continued availability of capital and financing, and general economic, market, or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions on the date the statements are made. No person or entity assumes any obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change
Wefunder means Wefunder Inc and its wholly owned subsidiaries: Wefunder Advisors LLC and Wefunder Portal LLC. This page is hosted by Wefunder Portal LLC
Wefunder Portal LLC is a member of the . Wefunder is risky. Don’t invest more than you can afford to lose. Financial Industry Regulatory Authority (FINRA) Investing on